Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05593497 · ClinicalTrials.gov registry record · Phase 2
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
A Phase 2 study of High-risk Prostate Cancer, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT05593497 is a Phase 2 study of High-risk Prostate Cancer that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 30 participants, below the 51-participant average among 4 other High-risk Prostate Cancer trials with a reported enrollment target (41% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT05593497, a Phase 2 study of High-risk Prostate Cancer, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized prostate cancers that are most resistant to standard treatments. This is a phase II research study. For this study, capivasertib, the study drug, will be taken with intensified androgen deprivation drugs (iADT; abiraterone and leuprolide) prior to radical prostatectomy. This study drug treatment will be evaluated to see if it is effective in shrinking and destroying prostate cancer tumors prior to surgery and to further evaluate its safety prior to prostate cancer surgery.
Conditions Studied
Interventions
- DRUG abiraterone acetate
- DRUG Capivasertib
Study Locations (6)
California
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA - West Los Angeles
New York
- James J. Peters VA Medical Center, Bronx, NY - The Bronx
Oregon
- VA Portland Health Care System, Portland, OR - Portland
South Carolina
- Ralph H. Johnson VA Medical Center, Charleston, SC - Charleston
Texas
- South Texas Health Care System, San Antonio, TX - San Antonio
Washington
- VA Puget Sound Health Care System Seattle Division, Seattle, WA - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05593497
The ClinicalTrials.gov registry entry for NCT05593497 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 4 other High-risk Prostate Cancer trials with a reported enrollment target (41% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-risk Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which abiraterone acetate is the first listed.
NCT05593497 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, New York, Oregon.
Frequently Asked Questions
What is clinical trial NCT05593497 about?
NCT05593497 is a clinical study titled "A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss". The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized prostate cancers that are most resistant to standard treatments. ...
What is the current status of trial NCT05593497?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-05-31. Estimated completion is 2027-08-01.
What conditions does trial NCT05593497 study?
This clinical trial studies the following conditions: High-risk Prostate Cancer.
What interventions are being tested in trial NCT05593497?
The interventions under investigation include: abiraterone acetate (DRUG), Capivasertib (DRUG).
Who is sponsoring clinical trial NCT05593497?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05593497 being conducted?
This trial has 6 study locations across California, New York, Oregon, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-risk Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
RECRUITING · Early Phase 1
-
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.